Related Experiment Video
Updated: Jul 14, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Genotype-specific weight loss treatment advice: how close are we?
Kristi B Adamo1, Frédérique Tesson
1Chalmers Research Group, Children's Hospital of Eastern Ontario Research Institute, and Laboratory of Genetics of Cardiac Diseases, University of Ottawa, Ontario, Canada. kadamo@cheo.on.ca
Summary
Individual weight loss success varies due to genetic factors influencing energy balance. Understanding gene-diet, gene-exercise, and gene-drug interactions is key for personalized obesity treatments.
Area of Science:
- Genetics and personalized medicine
- Obesity and metabolic health
Background:
- Rising global obesity rates present a significant healthcare challenge.
- Obesity is linked to serious conditions like type 2 diabetes, dyslipidemia, and cardiovascular disease.
- Weight loss is complex, influenced by genetics and environment, leading to variable individual responses.
Purpose of the Study:
- To review current evidence on how DNA variations in energy balance genes affect weight loss intervention outcomes.
- To explore the potential of nutrigenetic, actigenetic, and pharmacogenetic interactions in weight management.
Main Methods:
- Review of existing scientific literature on gene-diet, gene-exercise, and gene-pharmaceutical interactions.
- Analysis of studies investigating DNA sequence variations in energy balance-related genes.
Main Results:
- Evidence supports the role of DNA sequence variations in energy balance genes influencing weight loss response.
- Gene-diet, gene-exercise, and gene-drug interactions are emerging areas of research.
Conclusions:
- Genotype-specific weight loss strategies are a future goal, but require further research.
- Rigorous study designs are needed to validate findings and explore multi-gene interactions for personalized treatments.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...